This result suggests that the dynamics between TIL-CD8+ TCTL and M2-macrophage determine the inhibition or promotion of tumor growth in these three models, which is largely in agreement with the observations of increasing CD8+-TILs by anti-PD-1 treatment (manuscript in preparation) and depletion of CD8+ cells abrogating the efficacy. The gene discussed is CD8A; the disease is neoplasm.